Safety and Efficacy of P-ESWL and ERCP

Safety and Efficacy of Extracorporeal Shock Wave Lithotripsy and Endoscopic Retrograde Cholangiopancreatography for Pancreatic Stones

To determine the types, incidence and risk factors of adverse events after pancreatic extracorporeal shock wave lithotripsy (P-ESWL) and endoscopic retrograde cholangiopancreatography (ERCP), define the grading criteria of adverse events after P-ESWL and ERCP, and analyze the efficacy of P-ESWL and ERCP, which will provide evidence-based medical evidence to guide physicians' clinical practice.

Currently, pancreatic extracorporeal shock wave lithotripsy (P-ESWL) and endoscopic retrograde cholangiopancreatography (ERCP) has become the preferred treatment for pancreatic duct stones. Although some studies had confirmed the safety and efficacy of P-ESWL and ERCP, the sample size were small and the follow-up period were short. Therefore, investigators designed this study with a large sample and a long follow-up period to clarify the efficacy and safety of P-ESWL and ERCP, so as to guide clinical work, standardize the diagnosis and treatment process of adverse events.

Inclusion Criteria:

• Patients hospitalized in Changhai Hospital from 2011.03.01 to 2018.06.30.
• Painful patients with chronic pancreatitis.
• Patients who completed pancreatic extracorporeal shock wave lithotripsy.

Exclusion Criteria:

• Patients who diagnosed pancreatic cancer within 2 years after diagnosing chronic pancreatitis.
• Patients who refused to participate in the study.